Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges
Joint Authors
MacNabb, Claire
Patton, D.
Hayes, J. S.
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-22, 22 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-05-26
Country of Publication
Egypt
No. of Pages
22
Main Subjects
Abstract EN
It is estimated that over 200 million adults worldwide have osteoporosis, a disease that has increasing socioeconomic impact reflected by unsustainable costs associated with disability, fracture management, hospital stays, and treatment.
Existing therapeutic treatments for osteoporosis are associated with a variety of issues relating to use, clinical predictability, and health risks.
Consequently, additional novel therapeutic targets are increasingly sought.
A promising therapeutic candidate is sclerostin, a Wnt pathway antagonist and, as such, a negative regulator of bone formation.
Sclerostin antibody treatment has demonstrated efficacy and superiority compared to other anabolic treatments for increasing bone formation in both preclinical and clinical settings.
Accordingly, it has been suggested that sclerostin antibody treatment is set to achieve market approval by 2017 and aggressively compete as the gold standard for osteoporotic treatment by 2021.
In anticipation of phase III trial results which may potentially signify a significant step in achieving market approval here, we review the preclinical and clinical emergence of sclerostin antibody therapies for both osteoporosis and alternative applications.
Potential clinical challenges are also explored as well as ongoing developments that may impact on the eventual clinical application of sclerostin antibodies as an effective treatment of osteoporosis.
American Psychological Association (APA)
MacNabb, Claire& Patton, D.& Hayes, J. S.. 2016. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. Journal of Osteoporosis،Vol. 2016, no. 2016, pp.1-22.
https://search.emarefa.net/detail/BIM-1110164
Modern Language Association (MLA)
MacNabb, Claire…[et al.]. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. Journal of Osteoporosis No. 2016 (2016), pp.1-22.
https://search.emarefa.net/detail/BIM-1110164
American Medical Association (AMA)
MacNabb, Claire& Patton, D.& Hayes, J. S.. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. Journal of Osteoporosis. 2016. Vol. 2016, no. 2016, pp.1-22.
https://search.emarefa.net/detail/BIM-1110164
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1110164